BioSpace News Archive

Version 4.95 of Telemis-Medical offers greater scope for configuration, as well as addressing increasingly important GDPR and data security factors

Targeted, in-office suprachoroidal delivery of RGX-314 using the SCS Microinjector® may provide additional administration options for patients with wet AMD

Adagio Therapeutics, Inc., a company focused on the development of best-in-class antibodies to provide broad protection against SARS-CoV-2, SARS-CoV-1 and additional circulating bat coronaviruses, announced it has strengthened its management team with the addition of Eric Kimble as Chief Commercial Officer and Ed Campanaro as Senior Vice President of Clinical Operations.

Evogene Ltd., a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, announced it will be featured as a presenting company at the H.C. Wainwright 22nd Annual Global Investment Conference.

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will participate at the upcoming conferences in September 2020: H. C. Wainwright 22nd Annual Global Investment Conference Date: Monday,

ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Roger J. Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a Fireside Chat at the 2

LLS’s Innovative Beat AML Precision Medicine Clinical Trial Framework Will Expand to Test Treatment for Critically Ill Blood Cancer Patients with the Coronavirus

Research Collaboration on Two Targeted Oncology Programs in the Ras/Raf/MAP Kinase Pathway Redx to Receive $10 Million Upfront and $10 Million in Year 2 with up to $400 Million in Further Milestone Payments Plus Tiered Royalties on any Future Net Product Sales

Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020, at 9:20 a.m. ET. A live webcast of the presentation will be available on t

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced data presentations on abaloparatide-SC at the upcoming American Society for Bone and Mineral Research (ASBMR) 2020 Annual Virtual Meeting which will take place between September 11-15. “We are excited that data from our histomorphometry study, showing that treatment with abaloparatide results in significant increase in bone formation in postmenopausal women with